Spelling suggestions: "subject:"drug utilisation"" "subject:"rug utilisation""
71 |
An analysis of the usage of antibiotics in the private health care sector : a managed health care approach / Renier CoetzeeCoetzee, Renier January 2004 (has links)
The most frequent intervention performed by physicians is the writing of a prescription. Modern medicine has been remarkably effective in managing diseases. Medicines play a fundamental
role in the effectiveness, efficiency and responsiveness of health care systems. However,
health care expenditure is a great cause for concern and many nations around the world
struggle to contain rising health care costs.
Pharmaceutical benefit management programmes such as pharmacoeconomics, drug utilisation
review (DUR) and disease management have emerged as control tools to ensure cost effective
selection and use of medicine. These managed care instruments are often used to determine
whether new strategies or interventions, such as the implementation of a managed medicine
reference price list, are appropriate and have "value".
The general objective of this study was to investigate the influences of the implementation of a managed medicine reference price list on the usage and cost of antibiotic medicine in the
private health care sector of South Africa.
The research design used in this study was retrospective, non-experimental and quantitative.
The data used for the analysis were obtained over a two-year study period (1 May 2001 to 31
April 2003) from the central medicine claims database of Medschem&. Data was analysed
according to prevalence, cost and original (innovator) or generic medicine items. For the
purpose of this study antibiotics referred to beta-lactams (penicillins, cephalosporins and
"others"), erythromycin and other macrolides, tetracyclines, sulphonamides and combinations,
quinolones, chloramphenicol and aminoglycosides.
The results of the empirical investigation showed the total number of medicine items claimed
during the study period amounted to 49098736 medicine items having a total expenditure of
R7150344897.00. There was a decrease in the prevalence of original (innovator) products
during the two-year period. The prevalence of generic products increased from 25.87% to
32.47%.
A total of 4092495 antibiotic medicine items were claimed with a total cost of R526309279.43
representing 7.36% (n = R7150344897.00) of all pharmaceutical products purchased during the
two-year period. Original antibiotics had a prevalence of 42.32%, while generic antibiotics
constituted 57.68% of all antibiotic products claimed (n = 4092495). However, original
(innovator) products contributed 62.32% and generic products 37.68% to the total cost of all
antibiotics claimed.
It was concluded that the beta-lactam antibiotics represented 56.99% of all antibiotics claimed
(n = 4092495) and contributed 52.51% to the total antibiotic expenditure (n = R526309279.43)
for the two-year period. The average cost of beta-lactam items ranged between R112.88 *
69.95 and R122.18 + 81.42.
The Medschema Price List (MPL) was implemented in May 2001. The aim of this reference
pricing system was to allocate a ceiling price to a group of drugs, which are similar in terms of
composition, clinical efficacy, safety and quality, with the ultimate goal to reduce medicine
expenditure. During the year of implementation of the MPL 62.24% of beta-lactam antibiotics
claimed (n = 1303464) were MPL listed. These products contributed 43.25% to the total cost of
all beta-lactam antibiotics (n = R157142778.38). Medical aid companies reimbursed
R61649211.86 for penicillins claimed and MPL listed. If all penicillin products were claimed at
the ceiling price set by the MPL, a cost saving of 2.79% could have been achieved.
Cost analysis indicated that it is possible to reduce health care costs by implementing strategies
with the aim to reduce medicine cost. Further research, however, is necessary and in this
regard recommendations for further research were formulated. / Thesis (M.Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2005.
|
72 |
A longitudinal study of the usage of acid reducing medicine using a medicine claims database / Hendrika Nicolien Janse van RensburgJanse van Rensburg, Hendrika Nicolien January 2007 (has links)
Acid-related disorders are common, chronic conditions that have considerable impact on a patient's quality of life. In a study conducted by Majumdar et al. (2003:2411) the prevalence of chronic acid-related disorders was 2.3%. Acid-related disorders represent a major financial consideration with respect to the costs of drug prescribing (Whitaker, 1998:6). Health care cost increases each year. This leads to an increased interest in economic evaluation of health care and medical technologies (Anell & Svarvar, 2000:175). Health care providers no longer make treatment decisions independent of the consideration of the resultant cost. The treatment provided must not only provide value but the value must be documented to justify spending money. Economic evaluation research has emerged to offer guidance to policy makers, practitioners, health plans and institutions facing difficult treatment and coverage decisions (Ellis era/., 2002:271).
The main objectives of this study were to investigate the prescribing patterns and cost of acid reducing medicine with special reference to proton pump inhibitors and histamine-2 receptor antagonists in a section of the private health care sector of South Africa from 2001 to 2006. A longitudinal retrospective drug utilisation study was done on acid reducing medicine items claimed through a national medicine claims database. The five study years were 2001, 2002, 2004, 2005 and 2006. All the study years stretched from 1 January to 31 December.
It was determined that acid reducing medicine items prescribed decreased from 2.74% during 2001 to 2.50% during 2006 of all medicine items claimed. The same decreasing trend was observed regarding the cost of acid reducing medicine items. The cost percentage decreased from 4.89% (2001) to 3.72% (2006). However, the average cost per medicine item for the acid reducers increased by 5.35% from 2001 (R230.04 ± 176.29) to 2002 (R243.72 ± 184.18) and then decreased by 15.23% from 2002 to 2004. It again decreased with 15.05% from 2004
(R206.19 ± 179.42) to 2006 (R175.70 ± 172.55). The changes in the average cost of acid reducers were of no practical significance.
Proton pump inhibitors represented about half of the acid reducing medicine items prescribed and more than 70% of the total cost of acid reducing medicine items during the study years. The average cost of PPIs revealed a practical significant decrease (d > 0.8) from 2002 (R372.42 ± 156.62) to 2006 (R241.56 ± 177.21). H2RAs contributed between 15.00% and 18.26% of all acid reducing medicine items while contributing to between 9.68% and 16.85% of the total cost of all acid reducers.
The active ingredient most often prescribed was lansoprazole during 2001 and 2002, esomeprazole during 2004 and omeprazole during 2005 and 2006. Lanzor® 30mg was the acid reducer with the highest cost from 2001 to 2005, while Pariet® 20mg took the lead in 2006. Zantac® 150mg effervescent tablets were the H2RA, with the highest cost, during the five study years.
The percentage innovator items decreased by 4.50% from 2001 to 2002, increased by 1.01% from 2002 to 2004 and decreased again by 31.06% from 2004 to 2006. The slight increase in the percentage innovator medicine items claimed from 2002 to 2004 may be explained by the introduction of Nexiam® (esomeprazole) into the market in 2002. The total number of generic medicine items claimed contributed between 9.62% (n = R1 788 242.25) in 2001 and 30.75% (n = R3 196 163.34) in 2006 of the total cost of acid reducing medicine items.
The average cost per day of innovator medicine items was higher than the average cost per day of generic medicine items. This might be explained by a lower average cost for generic medicine items.
It was also determined that the prevalence of the two-drug regimens was the highest during the five study years. The Helicobacter pylori (H.pylori) eradication treatments, which included different antibiotics, increased from 2.72% in 2001 to 5.05% in 2006.
The PDD for most of the active ingredients of H2RAs and PPIs remained stable during the study years. However, it appears that the PDDs, of the PPIs, active ingredients were more constant than the PDDs, or the H2RAs, active ingredients. The median of the different PPI active ingredients was reasonably more constant than the median of the different H2RA active ingredients. Thus the changes between the PPIs' and H2RAs' active ingredients might be explained by the variation in the median (the number of days the relevant medicine item was claimed for).
It is then also recommended that the aspects of generic substitution as well as the usage of H2RAs as prescribed vs. self medication should be further investigated to increase possible cost savings. / Thesis (M.Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2008.
|
Page generated in 0.0844 seconds